The FDA needs a few more weeks to decide the fate of Moderna's RSV vaccine, the company announced. A decision is now slated ...
Moderna on Friday said the Food and Drug Administration has postponed an approval decision on its experimental vaccine for ... t expect major delays from here onwards and FDA should be able ...
US regulators’ decision on whether to approve Moderna Inc.’s vaccine for RSV has been delayed due to “administrative ...
The Food and Drug Administration (FDA) has informed Moderna that its review of the Biologics License Application (BLA) for mRNA-1345, an investigational respiratory syncytial virus (RSV ...
US regulators’ decision on whether to approve Moderna Inc.’s vaccine for RSV has been delayed due to ... get its second product to market. The FDA hasn’t informed Moderna of any issues ...
Moderna announced that the FDA had delayed approval of its RSV vaccine to the end of May due to "administrative constraints" ...
its investigational respiratory syncytial virus or RSV vaccine, will be delayed. In pre-market activity on the Nasdaq, Moderna shares were losing around 2.3 percent to trade at $119.91. The FDA ...
Moderna (NASDAQ:MRNA) shares are down just over 1% in early Friday trading after the company said the FDA ... RSV vaccine due to "administrative constraints." However, they remain on track for a ...